Journals / Türk Hematoloji Onkoloji Dergisi / 2003 / Cilt: 13 - Sayı: 4

Combined hormonotherapy and definitive radiation therapy in localized prostate adenocarcinoma

Lokalize prostat adenokanserlerinde hormon tedavisi ile birlikte küratif radyoterapi uygulaması

Pages
177–189
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This change in PSA levels before and after hormonotherapy was statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this prospective study, according to AJCC 1997 staging system Tl-T3b histologically proven prostate adenocarci-noma patients were treated.
📊
Key Findings & Data:Extracapsular extension, PSA$qeg$ 10 ng/dL and gleason score 7 and above were considered as high risk criteria and in case one of them is positive, the patient considered in the high risk group, otherwise treated in low risk group.
💡
Conclusion & Impact:This change in PSA levels before and after hormonotherapy was statistically significant (p
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

In this prospective study, according to AJCC 1997 staging system Tl-T3b histologically proven prostate adenocarci-noma patients were treated. Extracapsular extension, PSA$qeg$ 10 ng/dL and gleason score 7 and above were considered as high risk criteria and in case one of them is positive, the patient considered in the high risk group, otherwise treated in low risk group. Low risk patients were administered neoadjuvant hormonotherapy with Triptorelin acetate 3.75 mg/month IM and siproterin acetate 300 mg/15 days IM for only 12 weeks and thereafter were given radiotherapy. In high risk patients, we continued on hormonotherapy for 24 weeks more after the termination of radiotherapy. A total dose of 70 Gy external radiotherapy with 200 cGy daily fraction doses was delivered. In this study the preliminary results of 50 patients who completed radiotherapy between January 1998 and December 2000 were given. The medi-an age was 68 years (range 53-76). Their stages were distributed as follows: 21 (42%) T2a, 7 (14%) T2b, 18 (36%) T3a and 4 (8%). Twenty two patients had a gleason score above 6. Their pre-biopsy PSA levels ranged between 3,4 and 76.1 ng/mL (median 15 ng/mL). According to our risk criterias 10 patients were in the low risk group. Median follow up was 36 months. PSA levels measured before the initiation of radiotherapy were 0.02-16.7 ng/mL (median 1.05 ng/mL). This change in PSA levels before and after hormonotherapy was statistically significant (p

Özet

Prospektif olarak planlanan bu çalışma protokolüne, AJCC 1997 evreleme sistemine göre Tl-T3b NO MÖ prostat adenokanseri tanısı almış hastalar alınmıştır. Ekstrakapsüler yayılım, PSA $qeg$ 10ng/dL, Gleason skorunun 7 ve üzeri olması yüksek risk kriteri olarak kabul edilmekte ve bu kriterlerden birini taşıyan hasta yüksek risk grubuna ayrılmıştır. Bu kriterlerden hiçbirini taşımayan düşük riskli hasta grubuna 12 hafta süresince Triptorelin Asetat 3.75 mg İM 4 haftada bir ve 2 haftada bir Siproterin Asetat 300 mg IM'den oluşan hormon tedavisi sonrası küratif radyoterapi uygulanırken, yüksek riskli hasta grubunda radyoterapi sonrası 24 hafta süresince hormon tedavisine devam edilmiştir. Radyoterapi, prostat ve seminal vezikülleri l cm. emniyet sınırı ile kapsayacak şekilde 3 boyutlu planlama yapıldıktan sonra 200 cGy günlük fraksiyonlarla yedi ayrı alandan toplam 70 Gy olacak şekilde verilmiştir. Bu çalışmada Ocak 1998 - Aralık 2000 tarihleri arasında radyoterapisi tamamlanmış olan 50 hastanın ön değerlendirme sonuçları verilmektedir. Hastaların yaşları 53-76 (medyan 68 yaş) arasında değişmektedir. Yirmi bir hasta (% 42) T2a, 7 hasta (% 14) T2b, 18 hasta (%36) T3a ve 4 hasta (%8) T3b evrelerindedir. 22 hastanın Gleason skoru 7 ve üzerindedir. Biyop-si öncesi PSA değerleri 3.4-76.Ing/mL (medyan 15 ng/mL) arasındadır. Bu kriterlere göre 10 hasta düşük risk grubuna, 40 hasta yüksek risk grubuna alınmıştır. Çalışmaya alınan hastaların izlem süresi medyan 36 ay'dır. Neoad-juvan hormonoterapi sonrası PSA değerleri 0.02-16.7ng/mL (medyan 1.05 ng/mL), radyoterapi sonrası ise 0.01-10 ng/mL (medyan 0.67 ng/mL) arasındadır. Transrektal ultrasonografi ile ölçülen prostat hacimleri hormonoterapi önce-si 15-105 cc (medyan 38 cc), radyoterapi öncesi 14.5-65 cc (medyan 28 cc) olarak bulundu. Protokole dahil edilen yüksek risk grubundaki 11 hastada ve düşük risk grubunda l hastada biyokimyasal relaps tespit edildi. Bu hastalardan altısında radyoterapi sonrası uzak metastazlar gelişti. Üç olgu uzak metastaz sonrası, 3 olgu ise hastalık dışı nedenlerle kaybedilmiştir. RTOG kriterlerine göre 22 grade 1,18 grade II, 7 grade III akut rektal, 22 grade 1,23 grade II ve 2 grade III akut üretral toksisite saptandı. Radyoterapi sonrası en az 6 ay takip edilen hastalarımızda ciddi bir geç toksisite saptanmamıştır. Tedavi süresince, PSA düşüşü ve prostat hacim azalması istatistiki olarak anlamlı bulunmuştur. Bu çalışmada erken ve geç toksisiteler kabul edilebilir düzeyde görünmektedir.

🔖

Cite This Article

GÜRDALLI, S., ÖZYİĞİT, G., SARI, S., ÖNAL, C., AKYOL, F., YAPICI, B. (2022). Combined hormonotherapy and definitive radiation therapy in localized prostate adenocarcinoma. Türk Hematoloji Onkoloji Dergisi, Cilt: 13 - Sayı: 4, 177–189. https://ajindex.com/articles/624755

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94:2766-2792,2002
  2. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 82:1197-1207,1998
  3. Bagshaw MA, Ray GR, Cox RS. Radiotherapy of prostatic carcinoma: long- or short-term efficacy (Stanford University experience). Urology 25:17-23,1985
  4. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr:47-60,1988
  5. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299-1305,1988
  6. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 10:401-409,1984
  7. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128:502-504,1982
  8. Teh BS, Aguilar E, Aguilar L, et al. Late toxicity of a phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonotherapy in the treatment of prostate cancer. 45th Annual meeting of the American society for Therapeutic Radiology and Oncology. Salt Lake City, USA; 2003
  9. King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2:25-30,2003
  10. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116,2002
  11. ICRU. Prescribing, recording, and reporting photon beam therapy. Washington, DC: ICRU: International Commission on Radiation Units and Measurements; 1993
  12. ICRU. International Commission on Radiation Units and Measurements Report #62: Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). Washington, DC; 1999
  13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the Euopean Organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346,1995
  14. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat